

Medical Information Response

Wegovy™ (semaglutide) injection Dosing – Guidelines

Summary

- Wegovy™ should be initiated at a dose of 0.25 mg once weekly for 4 weeks.¹ The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached ([Table 1](#)).
 - If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.¹
 - If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks.¹ After 4 weeks, increase Wegovy™ to the maintenance 2.4 mg once-weekly. Discontinue Wegovy™ if the patient cannot tolerate the 2.4 mg dose.
 - Novo Nordisk does not recommend a dose escalation schedule other than what is outlined in the Wegovy™ Prescribing Information.
- Wegovy™ should be administered as a once-weekly subcutaneous injection on the same day each week, at any time of day, with or without meals.¹ Wegovy™ should be administered subcutaneously in the abdomen, thigh or upper arm.
- The maximum recommended dose of Wegovy™ is 2.4 mg once weekly.¹
- For information on using the Wegovy™ pen, please refer to the Instructions for Use.

Prescribing Information

Section 2.1: Dosage and Administration, Patient Selection

- Select adult patients for Wegovy™ treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management based on their body mass index (BMI). BMI is calculated by dividing weight (in kilograms) by height (in meters) squared.¹

Section 2.2: Dosage and Administration, Important Administration Instructions

- Prior to initiation of Wegovy™, train patients on proper injection technique.¹ Inspect Wegovy™ visually prior to each injection (only use if solution is clear, colorless and contains no particles). Administer Wegovy™ subcutaneously once-weekly, on the same day each week, at any time of day, in the abdomen, thigh or upper arm, with or without meals. The time of day and injection site can be changed without dose adjustment.

Section 2.3: Dosage and Administration, Recommended Dosage

- Initiate Wegovy™ with a dose of 0.25 mg once-weekly and follow the dose escalation schedule in [Table 1](#) to minimize gastrointestinal (GI) adverse reactions.¹

Table 1. Dose Escalation Schedule¹

Weeks	Weekly Dose	
1 through 4	0.25 mg	Dose escalation
5 through 8	0.5 mg	
9 through 12	1 mg	
13 through 16	1.7 mg	
Week 17 and onward	2.4 mg	Maintenance dose

- If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.¹
- The maintenance dose of Wegovy™ is 2.4 mg injected subcutaneously once-weekly.¹
- If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks.¹ After 4 weeks, increase Wegovy™ to the maintenance 2.4 mg once-weekly. Discontinue Wegovy™ if the patient cannot tolerate the 2.4 mg dose.
- In patients with type 2 diabetes, monitor blood glucose prior to starting Wegovy™ and during Wegovy™ treatment.¹

Maximum Dose

Per the Prescribing Information, the maximum recommended dose of Wegovy™ is 2.4 mg once-weekly.¹ Novo Nordisk cannot recommend the use of Wegovy™ in doses higher than those approved by the United States Food and Drug Administration.

Missed Dose

- If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer Wegovy™ as soon as possible.¹
- If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.¹
- If more than 2 consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate Wegovy™ and follow the dose escalation schedule ([Table 1](#)), which may reduce the occurrence of GI symptoms associated with reinitiation of treatment.¹

Section 1: Indications and Usage, Limitation of Use

- Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist.¹
- The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal preparations, have not been established.¹

If you would like to receive a copy of any of the published references cited in the response, please contact Novo Nordisk Medical Information at (800) 727-6500 or NNMedicalInformation@novonordisk.com.

References

1. Wegovy™ Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.